Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|February 5, 2019
Lipid Excipient Targets Multiple Dose Forms
Author(s)Pharmaceutical Technology Editors
A solid lipid excipient from ABITEC is designed for multiple dosing forms.
Advertisement
ABITEC Corporation, a manufacturer of specialty lipids, announced on Feb. 5, 2019 an expansion of its portfolio of excipients for multiple formulations. The new offering, CAPMUL GDB EP/NF, is a monographed glyceryl dibehenate designed for a range of dosing solutions.
The high-purity, highly-reproducible solid lipid excipient offers good flow and uniform particle size distribution for use in multiple formulations including tablets, hard gels, softgels, solid lipid nanoparticles, nano-structured lipids, granulations, multi-particulates, extrudates, congealing, and liquids, the company reports.
The company also offers specialty lipids for the manufacture of foams, creams, ointments, and lotions produced under cGMP manufacturing.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement